As one of only a handful of firms working in the hot area of induced pluripotent stem cells (iPSC), Fate Therapeutics Inc. inked a deal that could make its technology available across the research community, while boosting its own iPSC-based therapeutic efforts in the process. The San Diego-based firm disclosed on Oct. 14 a collaboration and license agreement with BD Biosciences, a unit of BD (Becton, Dickinson and Co.), of Franklin Lakes, N.J., to help …
No comments:
Post a Comment